Truist lowered the firm’s price target on HCA Healthcare (HCA) to $535 from $546 but keeps a Buy rating on the shares after the company posted Q1 adjusted EBITDA below consensus estimates. Weaker respiratory and more severe weather weighed on volumes, largely offset by better SDP, or Medicaid State-Directed Payments, the analyst tells investors in a research note. HCA’s financial flexibility remains attractive while its expansion pipeline is robust, Truist added.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target lowered to $534 from $593 at RBC Capital
- HCA Healthcare price target lowered to $436 from $481 at Wells Fargo
- HCA Healthcare price target lowered to $510 from $550 at KeyBanc
- HCA Healthcare price target lowered to $496 from $551 at Barclays
- HCA: Baxter Maintains Hold as Soft Underlying Trends Prompt Trimmed EBITDA Outlook and Price Target Cut to $436